Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 53 full-time employees. The firm focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The firm markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The firm`s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The firm holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
Website: aytubio.com



Growth: Bad revenue growth rate -17.6%, there is slowdown compared to average historical growth rates -13.4%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -15.9%. On average the margin is improving steadily. Gross margin is high, +66.1%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$5.89 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 216.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 172.0% higher than minimum and 19.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.0x by EV / Sales multiple

Key Financials (Download financials)

Ticker: AYTU
Share price, USD:  (0.0%)2.72
year average price 2.02  


year start price 1.39 2025-02-14

min close price 1.00 2025-04-07

max close price 2.77 2026-01-02

current price 2.72 2026-02-13
Common stocks: 6 279 744

Dividend Yield:  0.0%
EV / Sales: -0.2x
Margin (EBITDA LTM / Revenue): -15.9%
Fundamental value created in LTM:
Market Cap ($m): 17
Net Debt ($m): -31
EV (Enterprise Value): -14
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-03zacks.com

Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates

2025-11-13seekingalpha.com

Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript

2025-09-24accessnewswire.com

Aytu BioPharma to Present at Upcoming September 2025 Conferences

2025-09-23seekingalpha.com

Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript

2025-09-23accessnewswire.com

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

2025-06-06accessnewswire.com

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

2025-05-14seekingalpha.com

Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript

2025-05-07accessnewswire.com

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

2025-02-05accessnewswire.com

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

2024-12-03accesswire.com

Aytu BioPharma Disclosure Notification
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-06-30
symbol AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2024-11-13 2024-05-15 2024-02-14 2023-11-14 2023-05-11 2023-02-21 2022-11-14
acceptedDate 2025-11-13 16:11:15 2025-09-23 16:06:49 2024-11-13 17:20:28 2024-09-26 16:05:37 2024-05-15 16:11:00 2024-02-14 16:05:58 2023-11-14 16:05:46 2023-10-12 14:50:49 2023-05-11 16:03:34 2023-02-21 16:35:37 2022-11-14 16:07:54 2022-09-27 16:06:58 2021-09-28 16:23:00
calendarYear 2026 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
revenue 14M 66M 17M 65M 18M 23M 22M 107M 23M 26M 28M 97M 66M
costOfRevenue 5M 21M 5M 16M 6M 7M 7M 41M 10M 9M 10M 46M 36M
grossProfit 9M 46M 12M 49M 12M 16M 15M 67M 13M 17M 18M 50M 29M
grossProfitRatio 0.661 0.723 0.65 0.707 0.669 0.561 0.658 0.652
researchAndDevelopmentExpenses 0 1M 426 000 3M 619 000 524 000 604 000 4M 856 000 2M 1M 13M 6M
generalAndAdministrativeExpenses 5M 17M 5M 20M 5M 5M 7M 29M 7M 8M 7M 31M 26M
sellingAndMarketingExpenses 5M 21M 6M 22M 7M 7M 7M 41M 13M 11M 10M 39M 30M
sellingGeneralAndAdministrativeExpenses 10M 38M 11M 42M 12M 12M 14M 70M 20M 19M 17M 70M 56M
otherExpenses 444 000 14M 0 6M -1M -1M -709 000 10M 1M 1M 1M 78M 27M
operatingExpenses 11M 54M 11M 51M 13M 13M 15M 84M 22M 21M 20M 160M 88M
costAndExpenses 15M 74M 18M 67M 19M 19M 22M 124M 32M 30M 29M 207M 125M
interestIncome 0 0 0 0 0 0 0 0 0 0 0 14 000 0
interestExpense 516 000 4M 994 000 5M 0 0 0 5M -1M 3M 1M 147M 0
depreciationAndAmortization 803 000 5M 1M 7M 2M 2M 2M 9M 102 000 3M 2M 10M 9M
ebitda 3M -5M 4M 1M -2M 2M -2M -3M -9M -819 000 803 000 -28M -29M
ebitdaratio 0.236 0.236 -0.137 0.103 -0.068 -0.404 -0.031 0.029
operatingIncome -2M -8M -930 000 -2M -2M 2M -2M -17M -9M -4M -2M -110M -59M
operatingIncomeRatio -0.108 -0.056 -0.137 0.103 -0.068 -0.409 -0.16 -0.055
totalOtherIncomeExpensesNet 3M -6M 2M -9M -178 000 -2M -7M 14 000 2M -3M -1M 1M 840 000
incomeBeforeTax 2M -14M 1M -10M -3M 608 000 -8M -17M -7M -7M -3M -109M -58M
incomeBeforeTaxRatio 0.141 0.09 -0.147 0.027 -0.367 -0.317 -0.255 -0.104
incomeTaxExpense 0 437 000 405 000 2M -245 000 828 000 -2M 0 -1M 4M 1M -110 000 259 000
netIncome 2M -14M 1M -16M -3M -220 000 -8M -17M -6M -10M -4M -109M -58M
netIncomeRatio 0.141 0.089 -0.16 -0.01 -0.367 -0.257 -0.395 -0.153
eps -0.08 -2.16 0.2 -2.86 -0.52 -0.04 -1.48 -5.11 -1.57 -3.34 -33.66 -74.01 -69.6
epsdiluted -0.08 0.16 -0.52 -0.04 -1.48 -1.57 -3.34 -33.66
weightedAverageShsOut 9M 6M 7M 6M 6M 6M 5M 3M 4M 3M 125 895 1M 840 000
weightedAverageShsOutDil 19M 6M 9M 6M 6M 6M 5M 3M 4M 3M 125 895 1M 840 000
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-09-23 2024-09-26 2023-10-12 2022-09-27 2021-09-28
fiscalYear 2025 2024 2023 2022 2021
netInterestIncome -4M -5M -5M -147M 0
ebit -10M -5M -12M -38M -38M
nonOperatingIncomeExcludingInterest 2M 4M -5M -72M -21M
netIncomeFromContinuingOperations -14M -13M -17M -109M -58M
netIncomeFromDiscontinuedOperations 620 000 -3M 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -14M -16M -17M -109M -58M
epsDiluted -2.16 -2.86 -5.11 -74.01 -69.6

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-06-30
symbol AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2024-11-13 2024-05-15 2024-02-14 2023-11-14 2023-05-11 2023-02-21 2022-11-14
acceptedDate 2025-11-13 16:11:15 2025-09-23 16:06:49 2024-11-13 17:20:28 2024-09-26 16:05:37 2024-05-15 16:11:00 2024-02-14 16:05:58 2023-11-14 16:05:46 2023-10-12 14:50:49 2023-05-11 16:03:34 2023-02-21 16:35:37 2022-11-14 16:07:54 2022-09-27 16:06:58 2021-09-28 16:23:00
calendarYear 2026 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
cashAndCashEquivalents 33M 31M 20M 20M 20M 20M 20M 23M 19M 20M 24M 19M 50M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 33M 31M 20M 20M 20M 20M 20M 23M 19M 20M 24M 19M 50M
netReceivables 33M 31M 23M 24M 30M 29M 30M 29M 34M 26M 28M 22M 28M
inventory 10M 11M 12M 12M 13M 13M 13M 12M 14M 13M 13M 11M 16M
otherCurrentAssets 5M 0 6M 1M 8M 1M 749 000 867 999 1M 624 000 785 000 633 000 1M
totalCurrentAssets 81M 79M 61M 62M 71M 71M 71M 73M 78M 71M 74M 60M 105M
propertyPlantEquipmentNet 2M 2M 2M 2M 3M 3M 4M 4M 4M 5M 6M 6M 9M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 66M
intangibleAssets 41M 42M 51M 52M 54M 56M 57M 59M 63M 65M 69M 71M 85M
goodwillAndIntangibleAssets 41M 42M 51M 52M 54M 56M 57M 59M 63M 65M 69M 71M 151M
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 -11M
taxAssets 0 0 0 762 000 0 0 0 1M 0 0 0 0 11M
otherNonCurrentAssets 939 000 1M 2M 2M 889 000 907 000 772 000 792 000 892 000 821 000 829 000 766 000 465 000
totalNonCurrentAssets 44M 45M 55M 57M 58M 60M 62M 65M 69M 71M 76M 78M 160M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 125M 124M 116M 119M 129M 131M 133M 138M 147M 141M 150M 138M 266M
accountPayables 12M 11M 14M 10M 10M 10M 14M 13M 15M 11M 15M 11M 19M
shortTermDebt 2M 11M 6M 5M 26M 1M 1M 9M 14M 8M 9M 4M 25M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 43M 41M 0 0 0 0 0 57M
otherCurrentLiabilities 52M 26M 42M 42M 47M 9M 9M 41M 57M 49M 50M 24M 1M
totalCurrentLiabilities 66M 63M 61M 62M 84M 64M 65M 69M 85M 67M 73M 64M 109M
longTermDebt 0 11M 10M 11M 5M 15M 15M 21M 11M 15M 14M 14M 3M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 -11M
deferredTaxLiabilitiesNonCurrent 0 0 0 762 000 0 0 0 1M 0 0 0 0 11M
otherNonCurrentLiabilities 36M 30M 14M 17M 9M 19M 20M 6M 10M 14M -789 000 15M 13M
totalNonCurrentLiabilities 36M 42M 25M 29M 14M 34M 35M 29M 21M 28M 23M 29M 19M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 1M 0 577 000 783 000 845 000 1M 832 000 0 0 0 180 000 4M
totalLiabilities 102M 105M 86M 91M 98M 98M 101M 98M 106M 96M 96M 93M 128M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1000 1000 1000 1000 1000 1000 1000 1000 0 0 6000 0 3000
retainedEarnings -332M -334M -318M -320M -315M -312M -312M -304M -302M -294M -291M -287M -178M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 -0 0 0 0 0 0 -0 0
othertotalStockholdersEquity 355M 348M 346M 345M 344M 343M 340M 345M
totalStockholdersEquity 23M 19M 30M 28M 31M 33M 32M 39M 41M 46M 54M 44M 138M
totalEquity 23M 19M 30M 28M 31M 33M 32M 39M 41M 46M 54M 44M 138M
totalLiabilitiesAndStockholdersEquity 125M 116M 129M 131M 133M 147M 141M 150M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 125M 124M 116M 119M 129M 131M 133M 138M 147M 141M 150M 138M 266M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0 0 -11M
totalDebt 2M 23M 17M 16M 32M 16M 16M 30M 25M 22M 23M 18M 31M
netDebt -31M -8M -4M -4M 12M -3M -4M 7M 6M 3M -1M -1M -19M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-09-23 2024-09-26 2023-10-12 2022-09-27 2021-09-28
fiscalYear 2025 2024 2023 2022 2021
accountsReceivables 31M 24M 29M 22M 28M
otherReceivables 0 0 0 0 0
prepaids 6M 5M 8M 7M 10M
totalPayables 11M 10M 13M 11M 19M
otherPayables 0 0 0 0 0
accruedExpenses 15M 5M 6M 26M 6M
capitalLeaseObligationsCurrent 137 000 0 0 96 000 940 000
capitalLeaseObligationsNonCurrent 985 000 577 000 832 000 84 000 3M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 353M 348M 343M 331M 316M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-06-30
symbol AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU AYTU
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2024-11-13 2024-05-15 2024-02-14 2023-11-14 2023-05-11 2023-02-21 2022-11-14
acceptedDate 2025-11-13 16:11:15 2025-09-23 16:06:49 2024-11-13 17:20:28 2024-09-26 16:05:37 2024-05-15 16:11:00 2024-02-14 16:05:58 2023-11-14 16:05:46 2023-10-12 14:50:49 2023-05-11 16:03:34 2023-02-21 16:35:37 2022-11-14 16:07:54 2022-09-27 16:06:58 2021-09-28 16:23:00
calendarYear 2026 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
netIncome 2M -14M 1M -16M -3M -220 000 -8M -17M -7M -5M -3M -109M -58M
depreciationAndAmortization 803 000 5M 1M 7M 2M 2M 2M 9M 2M 2M 2M 10M 9M
deferredIncomeTax 0 0 0 0 0 659 000 -20 000 0 0 0 0 0 0
stockBasedCompensation 114 000 576 000 173 000 2M 811 000 820 000 930 000 6M 902 000 3M 1M 5M 4M
changeInWorkingCapital -23 000 -6M -854 000 -5M 416 000 -4M -1M -6M 4M -2M -10M -11M 2M
accountsReceivables -2M -8M 478 000 5M -522 000 479 000 -945 000 -7M -9M 2M -6M 7M 2M
inventory 1M 382 000 334 000 -5M -534 000 -117 000 -1M -4M -804 000 -79 000 -2M 1M 3M
accountsPayables 2M 287 000 3M -2M 95 000 -4M 914 000 2M 5M -4M 4M -8M -3M
otherWorkingCapital -750 000 1M -5M -3M 1M -99 000 -297 000 3M 9M -336 000 -5M -11M 596 000
otherNonCashItems -3M 11M -3M 10M 5M 110 000 6M 3M -3M -709 000 311 000 75M 18M
netCashProvidedByOperatingActivities -618 000 -2M -1M -1M -254 000 -135 000 -211 000 -5M -3M -2M -9M -29M -26M
investmentsInPropertyPlantAndEquipment 0 -228 000 -136 000 -329 000 0 0 0 0 0 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0 -5000 5000 -5000 0 -3M -481 000
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 517 000 -45 000 -174 000 -76 000 -4000 0 42 000
netCashUsedForInvestingActivites 0 381 000 -45 000 -174 000 -76 000 1000 -5000 42 000
debtRepayment 2M 0 -530 000 -23 000 -22 000 0 0 -31M
commonStockIssued 0 0 0 86 000 -160 000 1M 1M 10M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 0 911 000 555 000 -189 000 -3M 1M -3M 34M
netCashUsedProvidedByFinancingActivities 2M 911 000 530 000 -126 000 -3M 3M -2M 14M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 2M 11M 102 000 -3M 231 000 -435 000 -3M 4M -322 000 -4M 4M -31M 2M
cashAtEndOfPeriod 33M 31M 20M 20M 20M 20M 20M 23M 19M 20M 24M 19M 50M
cashAtBeginningOfPeriod 31M 20M 20M 23M 20M 20M 23M 19M 20M 24M 19M 50M 48M
operatingCashFlow -618 000 -2M -1M -1M -254 000 -135 000 -211 000 -5M -3M -2M -9M -29M -26M
capitalExpenditure 0 -3M -136 000 -329 000 0 0 0 0 0 0 0 0 0
freeCashFlow -618 000 -5M -1M -2M -254 000 -135 000 -211 000 -5M -3M -2M -9M -29M -26M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-09-23 2024-09-26 2023-10-12 2022-09-27 2021-09-28
fiscalYear 2025 2024 2023 2022 2021
otherInvestingActivities -2M 0 -112 000 -70 000 -2M
netCashProvidedByInvestingActivities -3M -329 000 -117 000 -3M -3M
netDebtIssuance 7M -2M -2M -5M -4M
longTermNetDebtIssuance 0 -3M -96 000 -1M -968 000
shortTermNetDebtIssuance 7M 832 000 -2M -4M -3M
netStockIssuance 15M 3M 16M 12M 40M
netCommonStockIssuance 15M 3M 16M 12M 40M
commonStockIssuance 15M 3M 16M 12M 40M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -6M -3M -4M -5M -6M
netCashProvidedByFinancingActivities 15M -1M 9M 2M 30M
incomeTaxesPaid 1M 2M 0 0 0
interestPaid 3M 4M 4M 3M 1M

Earning call transcript

2025 q4
2026-02-03 ET (fiscal 2026 q2)
2025 q3
2025-11-13 ET (fiscal 2026 q1)
2025 q2
2025-09-23 ET (fiscal 2025 q4)
2025 q1
2025-05-14 ET (fiscal 2025 q3)
2024 q4
2025-02-12 ET (fiscal 2025 q2)
2024 q3
2024-11-13 ET (fiscal 2025 q1)
2024 q2
2024-09-26 ET (fiscal 2024 q4)
2024 q1
2024-05-15 ET (fiscal 2024 q3)
2023 q4
2024-02-14 ET (fiscal 2024 q2)
2023 q3
2023-11-14 ET (fiscal 2024 q1)
2023 q2
2023-09-27 ET (fiscal 2023 q4)
2023 q1
2023-05-11 ET (fiscal 2023 q3)
2022 q4
2023-02-21 ET (fiscal 2023 q2)
2022 q3
2022-11-14 ET (fiscal 2023 q1)
2022 q2
2022-09-27 ET (fiscal 2022 q4)
2021 q3
2021-11-15 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-20 21:05 ET
Aytu Biopharma published news for 2025 q4
SEC form 8
2026-01-20 21:05 ET
Aytu Biopharma published news for 2025 q4
SEC form 8
2026-01-20 21:05 ET
Aytu Biopharma published news for 2025 q4
SEC form 10
2025-11-13 21:11 ET
Aytu Biopharma published news for 2025 q3
SEC form 8
2025-11-13 21:08 ET
Aytu Biopharma published news for 2025 q3
SEC form 8
2025-11-13 21:08 ET
Aytu Biopharma published news for 2025 q3
SEC form 10
2025-09-23 20:06 ET
Aytu Biopharma reported for 2025 q2
SEC form 8
2025-09-23 20:05 ET
Aytu Biopharma published news for 2025 q2
SEC form 8
2025-09-23 20:05 ET
Aytu Biopharma published news for 2025 q2
SEC form 8
2025-06-17 10:05 ET
Aytu Biopharma published news for 2025 q1
SEC form 8
2025-06-17 10:05 ET
Aytu Biopharma published news for 2025 q1
SEC form 8
2025-06-09 20:30 ET
Aytu Biopharma published news for 2025 q1
SEC form 8
2025-06-09 20:30 ET
Aytu Biopharma published news for 2025 q1
SEC form 8
2025-06-06 20:07 ET
Aytu Biopharma published news for 2025 q1
SEC form 8
2025-06-06 20:07 ET
Aytu Biopharma published news for 2025 q1
SEC form 8
2025-06-06 20:07 ET
Aytu Biopharma published news for 2025 q1
SEC form 10
2025-05-14 20:07 ET
Aytu Biopharma published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Aytu Biopharma published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Aytu Biopharma published news for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Aytu Biopharma reported for 2025 q1
SEC form 8
2025-02-12 00:00 ET
Aytu Biopharma published news for 2024 q4
SEC form 8
2025-02-12 00:00 ET
Aytu Biopharma published news for 2024 q4
SEC form 10
2025-02-12 00:00 ET
Aytu Biopharma reported for 2024 q4
SEC form 10
2024-11-13 17:20 ET
Aytu Biopharma reported for 2024 q3
SEC form 8
2024-11-13 16:05 ET
Aytu Biopharma published news for 2024 q3
SEC form 8
2024-11-13 16:05 ET
Aytu Biopharma published news for 2024 q3
SEC form 8
2024-11-13 16:05 ET
Aytu Biopharma published news for 2024 q3
SEC form 10
2024-11-13 00:00 ET
Aytu Biopharma published news for 2024 q3
SEC form 8
2024-09-26 00:00 ET
Aytu Biopharma published news for 2024 q2
SEC form 8
2024-09-26 00:00 ET
Aytu Biopharma published news for 2024 q2
SEC form 10
2024-09-26 00:00 ET
Aytu Biopharma reported for 2024 q2
SEC form 8
2024-05-15 16:12 ET
Aytu Biopharma published news for 2024 q1
SEC form 8
2024-05-15 16:12 ET
Aytu Biopharma published news for 2024 q1
SEC form 10
2024-05-15 16:11 ET
Aytu Biopharma reported for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Aytu Biopharma published news for 2024 q1
SEC form 8
2024-02-14 00:00 ET
Aytu Biopharma published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Aytu Biopharma published news for 2023 q4
SEC form 10
2024-02-14 00:00 ET
Aytu Biopharma reported for 2023 q4
SEC form 8
2023-11-14 16:10 ET
Aytu Biopharma published news for 2023 q3
SEC form 10
2023-11-14 16:05 ET
Aytu Biopharma reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Aytu Biopharma published news for 2023 q3
SEC form 8
2023-10-26 00:00 ET
Aytu Biopharma published news for 2023 q3
SEC form 10
2023-10-12 14:50 ET
Aytu Biopharma published news for 2023 q2
SEC form 10
2023-10-12 00:00 ET
Aytu Biopharma published news for 2023 q2
SEC form 8
2023-09-27 16:20 ET
Aytu Biopharma reported for 2023 q2
SEC form 6
2023-08-15 16:10 ET
Aytu Biopharma published news for 2023 q2
SEC form 6
2023-07-31 08:05 ET
Aytu Biopharma published news for 2023 q2
SEC form 6
2023-07-10 08:05 ET
Aytu Biopharma published news for 2023 q2
SEC form 6
2023-06-15 10:42 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-05-11 16:10 ET
Aytu Biopharma reported for 2023 q1
SEC form 10
2023-05-11 16:03 ET
Aytu Biopharma reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Aytu Biopharma reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-05-01 08:05 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-04-27 08:05 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-04-19 08:00 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-04-07 16:30 ET
Aytu Biopharma published news for 2023 q1
SEC form 6
2023-03-27 16:14 ET
Aytu Biopharma published news for 2022 q4
SEC form 8
2023-02-21 00:00 ET
Aytu Biopharma reported for 2022 q4
SEC form 10
2023-02-21 00:00 ET
Aytu Biopharma reported for 2022 q4
SEC form 8
2022-11-14 00:00 ET
Aytu Biopharma reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Aytu Biopharma reported for 2022 q3
SEC form 8
2022-09-28 00:00 ET
Aytu Biopharma reported for 2022 q2
SEC form 10
2022-09-27 00:00 ET
Aytu Biopharma reported for 2022 q2
SEC form 10
2022-05-16 00:00 ET
Aytu Biopharma reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Aytu Biopharma reported for 2022 q1
SEC form 10
2022-02-14 00:00 ET
Aytu Biopharma published news for 2021 q4
SEC form 8
2022-02-14 00:00 ET
Aytu Biopharma published news for 2021 q4
SEC form 10
2021-11-15 00:00 ET
Aytu Biopharma published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Aytu Biopharma published news for 2021 q3
SEC form 10
2021-09-28 00:00 ET
Aytu Biopharma published news for 2021 q2
SEC form 8
2021-09-27 00:00 ET
Aytu Biopharma published news for 2021 q2
SEC form 10
2021-05-17 00:00 ET
Aytu Biopharma published news for 2021 q1